Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.
The U.S. Patent and Trademark Office (USPTO) issued Patent Nos. US 12,453,494, US 12,458,257 and US 12,458,258. These patents strengthen the company’s competitive position and intellectual property protection as it advances its CBGM system toward commercialization.
Glucotrack’s device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
Glucotrack Chief Science Officer Mark Tapsak outlined how the system works at the American Diabetes Association’s (ADA) 85th Scientific Sessions in Chicago in June.
The company said last fall that it expects to submit the system for FDA investigational device exemption (IDE) this coming spring.
Glucotrack said the three new patents protect key technologies, including proprietary sensor chemistry, intravascular lead design and low-power electronics. It said the innovations bridge the gap between short-use subcutaneous sensors, like those from Abbott and Dexcom, and larger, pacemaker-class devices.
“These patents represent a significant milestone in protecting our innovative technology that is at the core of our CBGM system,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization. These patents establish important competitive barriers and strengthen our position to deliver a differentiated approach to diabetes management.”
